| Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma J Edeline, E Boucher, Y Rolland, E Vauléon, M Pracht, C Perrin, ... Cancer 118 (1), 147-156, 2012 | 356 | 2012 |
| DNA methylation in glioblastoma: impact on gene expression and clinical outcome A Etcheverry, M Aubry, M De Tayrac, E Vauleon, R Boniface, F Guenot, ... BMC genomics 11 (1), 1-11, 2010 | 273 | 2010 |
| Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial A Omuro, AA Brandes, AF Carpentier, A Idbaih, DA Reardon, ... Neuro-oncology, 2022 | 251 | 2022 |
| Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers T Avril, E Vauleon, E Chevet Oncogenesis 6 (8), e373-e373, 2017 | 246 | 2017 |
| Dual IRE 1 RN ase functions dictate glioblastoma development S Lhomond, T Avril, N Dejeans, K Voutetakis, D Doultsinos, M McMahon, ... EMBO molecular medicine 10 (3), e7929, 2018 | 155 | 2018 |
| Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell … J Guigay, A Aupérin, J Fayette, E Saada-Bouzid, C Lafond, M Taberna, ... The Lancet Oncology 22 (4), 463-475, 2021 | 146 | 2021 |
| 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The Lancet 393 (10191), 2591-2598, 2019 | 136 | 2019 |
| Overview of cellular immunotherapy for patients with glioblastoma E Vauleon, T Avril, B Collet, J Mosser, V Quillien Clinical and Developmental Immunology 2010, 2010 | 136 | 2010 |
| Human glioblastoma stem‐like cells are more sensitive to allogeneic NK and T cell‐mediated killing compared with serum‐cultured glioblastoma cells T Avril, E Vauleon, A Hamlat, S Saikali, A Etcheverry, C Delmas, S Diabira, ... Brain pathology 22 (2), 159-174, 2012 | 115 | 2012 |
| A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an … K Fizazi, A Maillard, N Penel, G Baciarello, D Allouache, G Daugaard, ... Annals of Oncology 30, v851, 2019 | 108 | 2019 |
| Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions T Avril, S Saikali, E Vauleon, A Jary, A Hamlat, M De Tayrac, J Mosser, ... Journal of neuroimmunology 225 (1-2), 22-33, 2010 | 89 | 2010 |
| Survival and prognostic factors in a series of adults with medulloblastomas L Riffaud, S Saikali, E Leray, A Hamlat, C Haegelen, E Vauleon, ... Journal of neurosurgery 111 (3), 478-487, 2009 | 86 | 2009 |
| The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 P Bady, S Kurscheid, M Delorenzi, T Gorlia, MJ van den Bent, ... Acta neuropathologica 135 (4), 601-615, 2018 | 82 | 2018 |
| LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 … J Bourhis, C Sire, Y Tao, L Martin, M Alfonsi, JB Prevost, M Rives, ... Annals of Oncology 31, S1168, 2020 | 71 | 2020 |
| Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the … L Lebellec, B Chauffert, JY Blay, A Le Cesne, C Chevreau, E Bompas, ... European Journal of Cancer 79, 119-128, 2017 | 68 | 2017 |
| Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression G Reyes-Botero, C Dehais, A Idbaih, N Martin-Duverneuil, M Lahutte, ... Neuro-oncology 16 (5), 662-670, 2014 | 68 | 2014 |
| A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN … XS Sun, C Sire, Y Tao, L Martin, M Alfonsi, JB Prevost, M Rives, C Lafond, ... Journal of Clinical Oncology 36 (15_suppl), 6018-6018, 2018 | 64 | 2018 |
| Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study J Edeline, JL Raoul, E Vauleon, A Guillygomac’h, K Boudjema, E Boucher World journal of gastroenterology: WJG 15 (6), 713, 2009 | 64 | 2009 |
| CD90 expression controls migration and predicts dasatinib response in glioblastoma T Avril, A Etcheverry, R Pineau, J Obacz, G Jegou, F Jouan, PJ Le Reste, ... Clinical Cancer Research 23 (23), 7360-7374, 2017 | 62 | 2017 |
| Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations D Figarella-Branger, POLA Network, K Mokhtari, POLA Network, ... Neuro-oncology 16 (9), 1244-1254, 2014 | 61 | 2014 |
